Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Which second-line treatment regimen should be used following relapse of platinum-sensitive ovarian cancer?

Nature Clinical Practice Oncology volume 4, pages 340–341 (2007)Cite this article

boxed-textPfisterer J et al. (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24: 4699–4707

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pfisterer J et al. (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24: 4699–4707

    Article  CAS  Google Scholar 

  2. duBois A et al. (2001) Second-line carboplatin and gemcitabine in platinum-sensitive ovarian cancer: a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) ovarian Cancer Study Group. Ann Oncol 12: 1115–1120

    Article  CAS  Google Scholar 

  3. Pfisterer J and Ledermann JA (2006) Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol 33 (Suppl 6): S12–S16

    Article  CAS  Google Scholar 

  4. Papadimitriou CA et al. (2004) Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study. Gynecol Oncol 92: 152–159

    Article  CAS  Google Scholar 

  5. Kose MF et al. (2005) A phase II study of gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma. Gynecol Oncol 96: 374–380

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. S Pecorelli is Chairman of the Department of Obstetrics and Gynecology and F Odicino is Consultant Physician in the Department of Obstetrics and Gynecology at the University of Brescia, Brescia, Italy.,

    Sergio Pecorelli & Franco Odicino

Authors
  1. Sergio Pecorelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Franco Odicino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sergio Pecorelli.

Ethics declarations

Competing interests

S Pecorelli and F Odicino have received reimbursement for symposia from Eli Lilly Co.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pecorelli, S., Odicino, F. Which second-line treatment regimen should be used following relapse of platinum-sensitive ovarian cancer?. Nat Rev Clin Oncol 4, 340–341 (2007). https://doi.org/10.1038/ncponc0795

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0795

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing